BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH
Portfolio Pulse from
Bio-Techne Corporation has announced a strategic partnership with ALZpath, Inc to advance research in neurodegenerative diseases, including Alzheimer's. This collaboration will utilize Bio-Techne's Ella™ platform and ALZpath's pTau217 antibody to develop a new assay.
November 18, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bio-Techne Corporation has entered a strategic partnership with ALZpath to enhance neurodegenerative disease research. This partnership will utilize Bio-Techne's Ella™ platform and ALZpath's pTau217 antibody, potentially boosting Bio-Techne's product offerings and market position in the biotech sector.
The partnership with ALZpath is likely to enhance Bio-Techne's product offerings in the neurodegenerative disease research space, potentially increasing demand for their Ella™ platform. This could positively impact Bio-Techne's market position and stock price in the short term.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90